Pharmacokinetics (PK) analysis is essential for understanding how a drug candidate is absorbed, distributed, metabolized, and eliminated in biological systems. For pharmaceutical and biotechnology teams, high-quality PK data helps clarify exposure profiles, compare lead compounds, support dose-route decisions, and identify development risks before greater resources are committed. BOC Sciences provides comprehensive pharmacokinetics analysis services for small molecules, peptides, oligonucleotides, biologics, metabolites, and complex therapeutic modalities. By integrating fit-for-purpose bioanalytical method development, sensitive quantitative platforms, robust sample processing, and expert PK interpretation, we help clients transform concentration-time data into actionable insights for drug discovery and development decision-making.
We develop fit-for-purpose quantitative methods to accurately measure drug and metabolite concentrations in plasma, serum, tissues, urine, bile, cerebrospinal fluid, and other biological matrices. Our team aligns assay design with compound properties, matrix complexity, and expected exposure range.
BOC Sciences generates reliable concentration-time profiles across single-dose, repeat-dose, route-comparison, and formulation-comparison studies. We support projects requiring rapid discovery screening as well as deeper exposure characterization.
Our scientists convert raw concentration data into meaningful PK parameters using non-compartmental and model-informed approaches. We help clients interpret exposure, clearance, distribution, and elimination behavior in the context of project objectives.
PK findings are most valuable when interpreted together with absorption, distribution, metabolism, and excretion data. BOC Sciences connects PK analysis with ADME testing, metabolite profiling, permeability, solubility, and stability information to provide a more complete understanding of compound behavior.
BOC Sciences provides tailored pharmacokinetics analysis solutions that help research teams understand exposure behavior, compare candidates, and reduce uncertainty in early development.
Our LC-MS testing platform provides high sensitivity and selectivity for small molecules, metabolites, peptides, lipids, and other chemically diverse analytes in complex biological matrices.
For compounds requiring robust chromatographic separation, our HPLC testing capabilities support reproducible quantification, impurity separation, and matrix-interference reduction across a wide range of sample types.
For volatile, semi-volatile, derivatized, or thermally stable analytes, GC-MS testing enables sensitive measurement of compounds that are not ideally suited to liquid chromatography workflows.
For proteins, antibodies, peptides, oligonucleotides, and other large or complex molecules, ligand-binding assay formats help quantify analytes where mass spectrometry may require additional enrichment or digestion strategies.
We use protein precipitation, liquid-liquid extraction, solid-phase extraction, tissue homogenization, enzymatic digestion, and derivatization strategies to improve recovery, reproducibility, and detection performance.
Our scientists apply non-compartmental analysis, compartmental modeling, exposure comparison, and statistical evaluation to translate concentration data into practical parameters for candidate selection and formulation strategy.
BOC Sciences supports pharmacokinetics analysis across diverse therapeutic modalities, matrices, and research objectives. Whether your project requires rapid compound ranking, tissue exposure profiling, or integrated exposure-metabolism interpretation, our team designs analytical workflows around the chemical and biological characteristics of your molecule.
Submit your molecule information, matrix type, sampling plan, or existing concentration data. Our PK scientists will design a practical analysis strategy aligned with your project goals.
We review the compound structure, modality, solubility, stability, expected exposure range, sample matrix, dosing route, and decision objective to define the appropriate PK analysis strategy.
Our team selects suitable detection platforms, optimizes extraction and chromatographic conditions, evaluates matrix effects, and establishes a calibration approach that supports reliable concentration measurement.
Biological samples are processed according to matrix-specific protocols and analyzed using optimized quantitative methods. Data review focuses on accuracy, reproducibility, signal stability, and concentration range suitability.
We calculate relevant PK parameters, interpret concentration-time behavior, compare groups or formulations, and deliver a clear report with data tables, curves, parameter summaries, and practical scientific conclusions.
Some promising compounds show low systemic exposure or rapid elimination, making detection difficult with standard methods. BOC Sciences improves analytical sensitivity through optimized sample extraction, concentration steps, chromatographic separation, ionization tuning, and matrix-matched calibration. These strategies help capture low-concentration data points that are critical for accurate AUC, half-life, and clearance estimation.
Biological matrices often contain endogenous components that suppress signals, overlap with analytes, or create inconsistent recovery. Our team applies tailored cleanup workflows, stable internal-standard strategies, chromatographic resolution, and matrix-effect evaluation to distinguish true analyte response from background interference and improve data confidence.
For compounds that degrade or convert quickly, conventional sample handling can distort the real exposure profile. BOC Sciences integrates temperature-controlled processing, stabilizer evaluation, rapid quenching, metabolite monitoring, and metabolite analysis and identification to connect parent-drug concentration changes with metabolic pathways.
Lead optimization programs often involve structurally related compounds with different absorption, clearance, distribution, or formulation behavior. We provide standardized PK data processing, exposure-normalized comparison, parameter ranking, and integrated interpretation with physicochemical and ADME datasets to help teams prioritize candidates with stronger development potential.
Collaborate with BOC Sciences to gain reliable PK data, practical interpretation, and integrated insight across bioanalysis, exposure profiling, ADME evaluation, and drug candidate optimization.
Our scientists combine analytical chemistry, sample preparation, pharmacokinetic interpretation, and drug development experience to ensure that concentration data are not only measured accurately but also interpreted meaningfully.
From mass spectrometry to chromatographic and ligand-binding approaches, we select technologies based on molecule type, matrix behavior, and sensitivity needs rather than forcing every project into a single workflow.
We support chemically diverse drug candidates, including small molecules, peptides, oligonucleotides, biologics, conjugates, and metabolites, with customized strategies for each analyte class.
Our reports present concentration-time curves, calculated parameters, comparative interpretation, and practical scientific recommendations that help project teams make informed next-step decisions.
Client Needs: A medicinal chemistry team required PK comparison of a series of heterocyclic kinase inhibitor analogs. Several candidates showed promising potency but produced weak plasma signals after oral dosing.
Challenges: The compounds had high protein binding, low plasma concentration in terminal time points, and matrix-dependent ion suppression, making AUC and half-life estimation unreliable using the client's initial method.
Solution: BOC Sciences redesigned the bioanalytical workflow by combining protein precipitation with solid-phase cleanup to improve analyte recovery and reduce matrix suppression. We optimized LC-MS/MS transitions, chromatographic separation, internal-standard response, and calibration range, then applied non-compartmental analysis to compare AUC, Cmax, Tmax, half-life, and apparent clearance across the analog series.
Outcome: The revised method improved terminal-phase detection and enabled clear differentiation between fast-clearing and exposure-favorable analogs, helping the client prioritize two compounds for further optimization.
Client Needs: A biotechnology group developing a cyclic peptide for inflammatory disease research needed plasma and tissue PK profiling to understand whether structural modification improved systemic persistence.
Challenges: The peptide showed adsorption to plastic surfaces, enzymatic degradation during sample handling, and different recovery behavior between plasma and tissue homogenates.
Solution: BOC Sciences established a peptide-specific workflow using low-binding consumables, cold-chain handling, stabilizing additives, and matrix-matched extraction protocols. We optimized LC-MS/MS conditions for peptide response, normalized tissue homogenate data, and compared plasma, liver, kidney, and target-tissue exposure to determine how structural modification influenced systemic persistence and distribution behavior.
Outcome: The optimized workflow revealed that lipidation increased systemic exposure and target-tissue persistence while reducing rapid early depletion, providing the client with a stronger basis for peptide structure refinement.
Client Needs: A drug discovery group observed rapid parent-drug disappearance for a prodrug-like ester compound and needed to determine whether low exposure was caused by poor absorption or fast metabolic conversion.
Challenges: Parent compound instability, multiple hydrolysis products, and overlapping chromatographic signals complicated direct interpretation of the concentration-time profile.
Solution: BOC Sciences developed a parallel parent-metabolite assay with immediate sample stabilization, optimized extraction, and chromatographic separation of hydrolysis products. We quantified parent and metabolite concentration-time profiles, calculated comparative exposure parameters, and integrated the results with pharmacokinetics and safety profiling data to distinguish absorption limitations from rapid metabolic conversion across formulations.
Outcome: The study demonstrated that parent-drug loss was primarily driven by rapid esterase-mediated conversion rather than absorption failure. The client used the results to guide prodrug redesign and formulation selection.
Pharmacokinetics (PK) analysis reveals how a drug candidate is absorbed, distributed, metabolized, and eliminated after administration. It helps development teams understand systemic exposure, clearance behavior, half-life, bioavailability, and dose-exposure relationships. These insights are especially valuable when comparing lead compounds, selecting promising candidates, optimizing dosing strategies, and identifying exposure-related risks before investing in more advanced development studies.
Common PK parameters include Cmax, Tmax, AUC, t1/2, CL, Vd, MRT, and bioavailability. Each parameter provides a different perspective on drug behavior, from peak concentration and total exposure to elimination rate and distribution volume. BOC Sciences supports customized PK study design, sample analysis, and parameter calculation to help clients generate interpretable data for compound evaluation and decision-making.
PK analysis is typically performed when researchers need to evaluate exposure profiles, compare administration routes, investigate rapid clearance, assess dose proportionality, or understand why a compound shows limited pharmacological response. Early PK data can reveal whether poor exposure, fast metabolism, low absorption, or unfavorable distribution may limit a candidate’s potential, enabling teams to refine compound design, formulation strategy, or experimental planning more efficiently.
PK analysis provides concentration-time data, while ADME studies help explain the biological and physicochemical factors behind those profiles. By integrating in vitro ADME findings with in vivo PK results, researchers can better understand absorption limitations, metabolic stability, protein binding effects, transporter involvement, and elimination pathways. This combined approach supports more rational compound optimization and helps development teams build a clearer picture of candidate behavior.
Clients should consider whether the service provider can design fit-for-purpose studies, handle diverse biological matrices, develop sensitive bioanalytical methods, and interpret PK parameters in the context of drug development goals. BOC Sciences offers flexible PK analysis services for small molecules, peptides, nucleic acid-related compounds, and other complex candidates, helping clients obtain reliable exposure data that supports informed research decisions.
BOC Sciences helped us understand why our lead compound showed strong activity but weak exposure. Their PK interpretation was practical, data-driven, and directly useful for our next design cycle.
— Dr. Rachel M., Director of Drug Discovery
Our molecule was difficult to quantify because of matrix interference and low terminal concentrations. Their method development team solved the problem and delivered clean, interpretable PK curves.
— Thomas L., Senior DMPK Scientist
The team understood the sample-handling risks for our peptide immediately. Their stabilization and extraction strategy made the final PK dataset much more reliable than our previous internal attempts.
— Dr. Elena K., Peptide Program Lead
What stood out was not only the analysis quality but also the interpretation. BOC Sciences connected PK results with ADME behavior and gave us a clear path for compound optimization.
— Michael R., Project Manager, Biotech R&D
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
